Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients
and is comprised of both arterial and venous thromboembolism (VTE). There are multiple …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

The establishment of prothrombotic states during cancer progression is well reported but the
precise mechanisms underlying this process remain elusive. A number of studies have …

Cancer-associated venous thrombosis (VTE) increases mortality and morbidity. However,
limited tools are available to identify high risk patients. Upon activation, neutrophils release …

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and
pulmonary embolism (PE), has been an important cause of sudden in-hospital death …

Purpose This study aimed to develop and validate a specific risk-stratification nomogram
model for the prediction of venous thromboembolism (VTE) in hospitalized patients with lung …

Simple Summary The duration of anticoagulant treatment for venous thromboembolism in
cancer patients is not well defined. The decision to suspend or re-introduce anticoagulation …

Patients with gastric cancer are at higher risk for venous thromboembolic events (VTE).
Majority of such patients are treated in ambulatory settings where thromboprophylaxis is not …

Background Cancer patients have an increased risk of venous thromboembolism (VTE).
Currently, the availability of highly discriminatory prediction models for VTE in cancer …

Background Fusobacterium nucleatum (F. nucleatum) often colonizes cancerous gastric
tissues and is characterized by the promotion of platelet aggregation and the development …